Maximizing Patent Exclusivity in Pharma

 


Drug development can consume over half of a 20-year patent term, leaving innovators with limited market protection. The U.S. Patent Term Extension (PTE) system (35 U.S.C. §156), introduced under Hatch-Waxman and the 1988 Generic Animal Drug Act, restores up to 5 years of lost exclusivity plus an optional pediatric extension by compensating for regulatory review delays. In the EU, Supplementary Protection Certificates (SPCs) offer similar relief, with a maximum of 5 years (plus 6 months for pediatric studies) scoped to active ingredients. 

To qualify for a PTE/SPC, patents must be unexpired, never previously extended, and tied to a first regulatory approval of a drug, device, or other regulated product. Applications must be filed promptly following approval and adhere to precise calculation rules that factor out pre-grant delays and periods of applicant inactivity. 

With PTE/SPCs, companies gain vital revenue to recoup the $2.6 billion average R&D cost per drug, incentivize investment in complex therapies, and balance timely generic entry with long-term innovation. A well-planned PTE/SPC strategy aligned with global regulatory timelines can extend exclusivity and bolster your patent portfolio worldwide. 

Read the full analysis and step-by-step guide here: Patent Term Extensions & SPCs 

Comments

Popular posts from this blog

Free and Paid Patent Databases You Need to Know in 2026

Quantum Computing Leadership Through the Lens of Patents

Why Patent Search Is Moving Beyond Keywords